nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.11.2014 | Gynecologic Endocrinology and Reproductive Medicine

Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model

verfasst von: Yavuz Simsek, Mehmet Gul, Ercan Yilmaz, Ibrahim Halil Ozerol, Elif Ozerol, Hakan Parlakpinar

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to examine the effects of atorvastatin in the treatment of experimental endometriosis.

Methods

Endometriosis was induced in 24 female rats. 4 weeks after the procedure dimensions of the foci were recorded. Rats were divided into three groups: in Group 1 (n = 8), a daily dose of 10 mg/kg atorvastatin was given for 14 days. In the second group (n = 8), a single dose of 1 mg/kg leuprolide acetate was injected intraperitoneally. The rats in Group 3 (n = 8) were received 1 mg/kg i.p. 0.9 % NaCl. At the end of the treatment, laparotomy was performed, and the dimensions of the endometriotic foci were recorded. Biochemical, histopathological and immunohistochemical studies were performed and nociception was compared in groups.

Results

Atorvastatin treatment exhibited significant analgesic activity in hot plate model (P = 0.022). The serum hs-CRP and tumor necrosis TNF-α levels were similar between the Group 2 and Group 3 (P > 0.05); however atorvastatin caused significant decrease in both serum markers. The histological and immunohistochemical scores were also found to be markedly lower in Group 1 and Group 2 (P < 0.05).

Conclusion

Atorvastatin treatment may have a therapeutic potential in the treatment of endometriosis through its anti-inflammatory and anti-nociceptive properties.

Vignali M, Infantino M, Matrone R, Chiodo I, Somigliana E, Busacca M, Viganò P (2002) Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril 78(4):665–678PubMedCrossRef

Giudice LC, Kao LC (2004) Endometriosis. Lancet 364(9447):1789–1799PubMedCrossRef

Matarese G, De Placido G, Nikas Y, Alviggi C (2003) Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends Mol Med 9(5):223–228PubMedCrossRef

Olivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M, Meresman G (2008) Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 23(12):2701–2708. doi:10.1093/humrep/den315 PubMedCrossRef

Celik O, Hascalik S, Elter K, Tagluk ME, Gurates B, Aydin NE (2008) Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways. Hum Reprod 23(11):2458–2465. doi:10.1093/humrep/den246 PubMedCrossRef

Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D (2006) Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest 62(3):139–147PubMedCrossRef

Kappou D, Matalliotakis M, Matalliotakis I (2010) Medical treatments for endometriosis. Minerva Ginecol 62(5):415–432PubMed

Jacobson TZ (2011) Potential cures for endometriosis. Ann N Y Acad Sci 1221:70–74. doi:10.1111/j.1749-6632.2010.05933.x PubMedCrossRef

Wang F, He YL, Peng DX, Liu MB (2005) Expressions of nuclear factor-kappaB and intercellular adhesion molecule-1 in endometriosis. Di Yi Jun Yi Da Xue Xue Bao 25:703–705PubMed

10.

Clearfield M, Whitney EJ, Weis S, Downs JR, Shapiro DR, Stein EA, Watson DJ, Langendörfer A, Beere PA, Stamler J, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622PubMedCrossRef

11.

Ghaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP (2010) Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology 18(4):169–177. doi:10.1007/s10787-010-0044-6 PubMedCrossRef

12.

Taubes G (2002) Does inflammation cut to the heart of the matter? Science 296:242–245PubMedCrossRef

13.

Schönbeck U, Libby P (2004) Inflammation, immunity, and HMGCoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:8–26CrossRef

14.

Grip O, Janciauskiene S, Bredberg A (2008) Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol 155:1085–1092. doi:10.1038/bjp.2008.369 PubMedCrossRefPubMedCentral

15.

Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P (2008) Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57:380–386. doi:10.1016/j.metabol.2007.10.014 PubMedCrossRef

16.

Gross GH (1977) A technique for sustained synchronization of hamster estrous cycles by hormonal means. Horm Behav 9:23–31PubMedCrossRef

17.

Vernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44:684–694PubMed

18.

Birnbaum Y, Lin Y, Ye Y, Merla R, Perez-Polo JR, Uretsky BF (2008) Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther 13(1):72–79. doi:10.1177/1074248407312839 PubMedCrossRef

19.

Dogan E, Saygili U, Posaci C, Tuna B, Caliskan S, Altunyurt S, Saatli B (2004) Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 82(Suppl 3):1115–1120PubMedCrossRef

20.

Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF (1984) Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230(2):341–348PubMed

21.

Forster MJ, Lal H (1999) Estimating age-related changes in psychomotor function: influence of practice and of level of caloric intake in different genotypes. Neurobiol Aging 20(2):167–176PubMedCrossRef

22.

Yucel A, Aydogan MS, Parlakpinar H, Erdogan MA, Kurt A, Ucar M, Durmus M (2012) Effects of propofol and dexmedetomidine on motor coordination and analgesia: a comparative analysis. Int J Clin Pharmacol Ther 50(9):678–682. doi:10.5414/CP201696 PubMedCrossRef

23.

Simsek Y, Celik O, Karaer A, Gul M, Yılmaz E, Koc O, Colak C, Zengin S, Aydin NE (2012) Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis. Arch Gynecol Obstet 286(3):777–783. doi:10.1007/s00404-012-2390-7 PubMedCrossRef

24.

Kianpour M, Nematbakhsh M, Ahmadi SM (2012) C-reactive protein of serum and peritoneal fluid in endometriosis. Iran J Nurs Midwifery Res 17(2 Suppl 1):S115–S119PubMedPubMedCentral

25.

Lermann J, Mueller A, Körber F, Oppelt P, Beckmann MW, Dittrich R, Renner SP (2010) Evaluation of high-sensitivity C-reactive protein in comparison with C-reactive protein as biochemical serum markers in women with endometriosis. Fertil Steril. 93(7):21–2129. doi:10.1016/j.fertnstert.2009.01.072

26.

Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, Barros H (2006) Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 273(4):227–231PubMedCrossRef

27.

Jialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44:6–11PubMedCrossRef

28.

Scholl B, Bersinger NA, Kuhn A, Mueller MD (2009) Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis. Gynecol Endocrinol 25(11):701–706. doi:10.3109/09513590903159680 PubMedCrossRef

29.

Lee GH, Choi YM, Kim SH, Hong MA, Oh ST, Lim YT, Moon SY (2008) Association of tumor necrosis factor-{alpha} gene polymorphisms with advanced stage endometriosis. Hum Reprod 23(4):977–981. doi:10.1093/humrep/den016 PubMedCrossRef

30.

Eisermann J, Gast MJ, Pineda J, Odem RR, Collins JL (1988) Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril 50(4):573–579PubMed

31.

Iwabe T, Harada T, Terakawa N (2002) Role of cytokines in endometriosis-associated infertility. Gynecol Obstet Invest 53(Suppl 1):19–25PubMedCrossRef

32.

Oktem M, Esinler I, Eroglu D, Haberal N, Bayraktar N, Zeyneloglu HB (2007) High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 22(5):1474–1480PubMedCrossRef

33.

Rodriguez AL, Wojcik BM, Wrobleski SK, Myers DD Jr, Wakefield TW, Diaz JA (2012) Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 33(4):371–382. doi:10.1007/s11239-012-0687-9 PubMedCrossRefPubMedCentral

34.

Garcia GG, Miranda HF, Noriega V, Sierralta F, Olavarría L, Zepeda RJ, Prieto J (2011) Antinociception induced by atorvastatin in different pain models. Pharmacol Biochem Behav 100(1):125–129. doi:10.1016/j.pbb.2011.08.007 PubMedCrossRef

35.

Santodomingo-Garzón T, Cunha TM, Verri WA Jr, Valério DA, Parada CA, Poole S, Ferreira SH, Cunha FQ (2006) Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol 149(1):14–22PubMedCrossRefPubMedCentral

Titel: Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model
verfasst von: Yavuz Simsek
Mehmet Gul
Ercan Yilmaz
Ibrahim Halil Ozerol
Elif Ozerol
Hakan Parlakpinar
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 5/2014
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-014-3295-4

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model